

**IARC Handbooks of Cancer Prevention**  
**VOLUME 18: CERVICAL CANCER SCREENING**  
**Lyon, France: 12–16 October 2020**

**PRELIMINARY LIST OF PARTICIPANTS**

**IARC requests that you do not contact or lobby meeting participants, send them written materials, or offer favours that could appear to be linked to their participation. (You may send pertinent written materials to IARC.) IARC will ask participants to report all such contacts and will publicly reveal any attempt to influence the meeting. Thank you for your cooperation.**

**Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.**

### **Members**

Silvina Arrossi, Center for the Study of State and Society/National Council for Scientific and Technical Research, Argentina  
Karima Bendahhou, Casablanca Cancer Registry, Morocco  
Johannes Berkhof, Amsterdam University Medical Centers, The Netherlands  
Julia Brotherton, Victorian Cytology Service Foundation Limited, Australia<sup>1</sup>  
Karen Canfell, Cancer Council New South Wales, Australia  
Mike Chirenje, University of Zimbabwe College of Health Sciences, Zimbabwe  
Michael H. Chung, Aga Khan University, Kenya  
Marta del Pino, Hospital Clinic de Barcelona, Spain  
Silvia de Sanjosé, Program for Appropriate Technology in Health, USA<sup>2</sup>  
Miriam Elfström, Karolinska Institutet, Sweden<sup>3</sup>  
Eduardo Franco, McGill University, Canada<sup>4</sup>  
Paolo Giorgi Rossi, Local Health Authority of Reggio Emilia, Italy  
Chisato Hamashima, Teikyo University/National Cancer Center, Japan  
Françoise Hamers, National Public Health Agency, France  
Simon Herrington, University of Edinburgh, United Kingdom  
Rachel Kupets, University of Toronto, Canada  
Anne Mackie, Public Health England Screening, United Kingdom  
Philippe Mayaud, London School of Hygiene & Tropical Medicine, United Kingdom  
Raúl Murillo, Hospital Universitario San Ignacio, Colombia  
Suleeporn Sangrajrang, National Cancer Institute, Thailand  
Rengaswamy Sankaranarayanan, Research Triangle Institute International India, India  
Mona Saraiya, Centers for Disease Control and Prevention, USA  
Mark Schiffman, National Cancer Institute, USA<sup>5</sup>  
Robert Smith, American Cancer Society, USA  
Nicolas Wentzensen, National Cancer Institute, USA  
Fanghui Zhao, Chinese Academy of Medical Sciences, China

### **Invited Specialists**

Marc Arbyn, Sciensano, Belgium<sup>6</sup>  
Walter Prendiville, University of Pittsburgh Medical Centre, Ireland (retired)<sup>7</sup>

### **Representative of national and international health agencies**

Carolina Wiesner, Colombian National Cancer Institute, Colombia

<sup>1</sup> Julia Brotherton reports that her unit at VCS Population Health benefits from research funding and equipment from Roche, Seegene, Cepheid, and Becton Dickinson.

<sup>2</sup> Silvia de Sanjosé reports that her unit at PATH benefited from research support from Merck.

<sup>3</sup> Miriam Elfström reports that her unit at Karolinska Institutet benefited from non-monetary research support from Sanofi Pasteur MSD SNC.

<sup>4</sup> Eduardo Franco reports being editor-in-chief of the journals *Preventive Medicine* and *Preventive Medicine Reports*.

<sup>5</sup> Mark Schiffman reports that his unit at the National Cancer Institute benefited from equipment and supplies from Qiagen and MobileODT.

<sup>6</sup> Marc Arbyn reports that his unit at Sciensano benefits from non-monetary support from manufacturers of human papillomavirus (HPV) assays and devices.

<sup>7</sup> Walter Prendiville reports holding stocks in NSV, receiving consultancy fees from Koru Auckland, and receiving royalties from Utah Medical Products, Inc. for patent #5951550.

***IARC Handbooks of Cancer Prevention***  
**VOLUME 18: CERVICAL CANCER SCREENING**  
**Lyon, France: 12–16 October 2020**

**Observer**

Jae-Weon Kim, Seoul National University, Republic of Korea

**IARC/WHO secretariat**

Maribel Almonte, Head, Prevention and Implementation Group  
Armando Baena, Prevention and Implementation Group  
Partha Basu, Head, Screening Group  
Iacopo Baussano, Infections and Cancer Epidemiology Group  
Véronique Bouvard, IARC Handbooks Group (*Co-Responsible Officer, Co-Rapporteur*)  
Nathalie Broutet, WHO headquarters  
Citadel Cabasag, Section of Cancer Surveillance  
Gary Clifford, Head, Infections and Cancer Epidemiology Group  
Ian Cree, Head, Section of Evidence Synthesis and Classification  
Hugo de Vuyst, Prevention and Implementation Group (unable to attend)  
Linda Eckert, WHO headquarters (unable to attend)  
Carolina Espina Garcia, Section of Environment and Radiation  
Elena Fidarova, WHO headquarters  
Mathilde Forestier, Visiting Scientist, Prevention and Implementation Group  
John Grove, WHO headquarters  
Isabelle Heard, Visiting Scientist, Prevention and Implementation Group  
Rolando Herrero, Visiting Scientist, Prevention and Implementation Group (unable to attend)  
Blanca Iciar Indave, WHO Classification of Tumours Group (*Co-Rapporteur*)  
Béatrice Lauby-Secretan, Head, IARC Handbooks Group (*Co-Responsible Officer, Co-Rapporteur*)  
Isabel Mosquera Metcalfe, Screening Group (*Co-Rapporteur*)  
Karen Müller, Communications Group (*Editor*)  
Tatiana Ramirez, Prevention and Implementation Group  
Maryluz Rol, Prevention and Implementation Group  
Guglielmo Ronco, Visiting Scientist, Infections and Cancer Epidemiology Group  
Nancy Santesso, WHO headquarters  
Catherine Sauvaget, Screening Group  
Farida Selmouni, Screening Group  
Vitaly Smelov, Prevention and Implementation Group (unable to attend)  
Salvatore Vaccarella, Section of Cancer Surveillance  
Patricia Villain, Screening Group

**NOTE REGARDING CONFLICTS OF INTERESTS:** Each participant first received a preliminary invitation with the request to complete and sign the IARC/WHO Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial and non-financial interests (e.g. public statements and positions related to the subject of the meeting).

Official invitations were extended after careful assessment of any declared interests that might constitute a real or perceived conflict of interest. Pertinent and significant conflicts are disclosed here. Information about other potential conflicts that are not disclosed may be sent to the Head of the IARC Handbooks Group at [ihb@iarc.fr](mailto:ihb@iarc.fr).

Participants identified as Invited Specialists will not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations will be updated and reviewed again at the opening of the meeting.